Moreover, it is worth mentioning that monoclonal antibodies employed in the treatment of Alzheimer’s disease exhibit intricate interactions with a spectrum of cellular proteins beyond the well-studied tau protein and beta-amyloid. This evidence concerns the gene YWHAQ and Alzheimer disease.